CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
Placebo oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04210986
NCT04210986Phase 2Completed
CompareCT.gov

Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial

Steadman Philippon Research Institute·interventional·Posted Dec 26, 2019·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating Fisetin and Placebo oral capsule for Osteoarthritis, Knee. Completed, enrolled 75 participants across 1 site.

Detailed Summary

Phase I/II randomized, double-blind, placebo-controlled clinical trial to test the safety and efficacy of Fisetin for treating mild to moderate osteoarthritis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited States
CollaboratorsUnited States Department of Defense, Office of Naval Research (ONR)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 26, 2019
Enrollment StartJan 6, 2020
Primary CompletionJan 5, 2023
Study CompletionFeb 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.5 years ago

Interventions

Fisetindietary

Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.

Placebo oral capsuledrug

Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.